Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality
Phytomedicine · 2025
DOI: 10.1016/j.phymed.2025.157124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Ying Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Liaoning Key Lab of Targeting Drugs for Hematological Malignancies, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, …. Hauptthemen laut MEDLINE: Homoharringtonine, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Harringtonines. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Samuel Waxman Cancer Research Foundation.
Abstract (Originalsprache)
BACKGROUND: Homoharringtonine (HHT), a natural product used clinically to treat acute myeloid leukemia (AML) in combination with chemotherapy, induced transient remission in 25 % of unclassified AML patients when administered alone. Recent studies showed that HHT could be combined with targeting agents for AML treatment. However, the rationales of these combinations require further exploration to optimize therapeutic efficacy. PURPOSE: To explore the sensitive subgroup of AML cells to HHT and to evaluate its optimal combinations with FLT3-ITD or Bcl-2 inhibitors based on apoptosis induction. METHODS: AML cell lines harboring FLT3-ITD mutation and wild-type FLT3 were used to compare the apoptosis induction of HHT alone and in combination with venetoclax or FLT3-ITD inhibitor. siRNA and Western blotting were used to identify the key factors in the apoptosis induction. Xenograft models were used to test the in vivo antileukemia efficacy and toxicity. RESULTS: FLT3-ITD AML cell lines and primary AML cells exhibited greater sensitivity to HHT-induced apoptosis and in vivo antileukemia effects than FLT3 wild-type cells. HHT induces apoptosis through repressing the antiapoptotic protein Mcl-1 and activating the proapoptotic protein Bax, which is attenuated by Mcl-1 overexpression and Bax knockdown. HHT in combination with Bcl-2 inhibitor venetoclax induce synergistic apoptosis across all cell lines with enhanced toxicity observed in vivo. HHT plus FLT3 inhibitors, including midostaurin, quizartinib, gilteritinib and sorafenib, induce selective synergistic apoptosis in FLT3-ITD AML cells, with the most potent effect observed in the combination of HHT and quizartinib. HHT plus quizartinib significantly prolonged FLT3-ITD AML xenograft survival without causing toxicity. CONCLUSIONS: FLT3-ITD AML cells represent a responsive subgroup to HHT treatment in vitro and in vivo. The combination of HHT and quizartinib demonstrates optimal efficacy and selectivity against FLT3-ITD AML cells in xenografts, with no observed toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liaoning Key Lab of Targeting Drugs for Hematological Malignancies, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China.
- Department of Hematology, Northern Theater General Hospital, Shenyang 110016, PR China.
- Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, PR China.
- The Division of Hematology/Oncology, Department of Medicine, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA.
- Liaoning Key Lab of Targeting Drugs for Hematological Malignancies, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Electronic address: 541169739@qq.com.
- Liaoning Key Lab of Targeting Drugs for Hematological Malignancies, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Electronic address: Jingyk@syphu.edu.cn.
Förderung
- Samuel Waxman Cancer Research Foundation
Zitieren
APA
Li, Y., Gao, X., Zhang, H., Qiu, Y., Chai, M., Liu, J., Yan, X., Waxman, S., Zhang, J., & Jing, Y. (2025). Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157124
Vancouver
Li Y, Gao X, Zhang H, Qiu Y, Chai M, Liu J, et al. Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157124
BibTeX
@article{Li2025,
author = {Li, Ying and Gao, Xiaoxiao and Zhang, Huimin and Qiu, Yang and Chai, Meng and Liu, Jinghua and Yan, Xiaojing and Waxman, Samuel and Zhang, Jingyi and Jing, Yongkui},
title = {Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2025.157124}
}
EUVIMED